An FXR agonist and inhibitor of FABP1
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ZLY28

Item No. 38864

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-[4′-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy][1,1′-biphenyl]-3-yl]-cyclopropanecarboxylic acid
CAS Number
3004676-77-8
Molecular Formula
C29H23Cl2NO4
Formula Weight
520.4
Purity
≥90%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/ml
λmax
265 nm
SMILES
ClC1=CC=CC(Cl)=C1C2=NOC(C3CC3)=C2COC4=CC=C(C5=CC=CC(C6(CC6)C(O)=O)=C5)C=C4
InChi Code
InChI=1S/C29H23Cl2NO4/c30-23-5-2-6-24(31)25(23)26-22(27(36-32-26)18-7-8-18)16-35-21-11-9-17(10-12-21)19-3-1-4-20(15-19)29(13-14-29)28(33)34/h1-6,9-12,15,18H,7-8,13-14,16H2,(H,33,34)
InChi Key
GFQRXOXNBQDNBC-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $156

    Add

    5 mg

    $659

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    ZLY28 is a farnesoid X receptor (FXR) agonist and an inhibitor of fatty acid binding protein 1 (FABP1).1 It selectively induces reporter gene expression in HepG2 cells expressing human FXR (EC50 = 143 nM) over cells expressing 19 other receptors (EC50s = >10,000 nM for all). ZLY28 selectively inhibits FABP1 (IC50 = 2.7 µM) over FABP3 (IC50 = >30 µM) but also inhibits FABP4 (IC50 = 6.3 µM). In vivo, ZLY28 (20 mg/kg) induces FXR-related gene expression in the ileum but not the liver in a mouse model of carbon tetrachloride-induced non-alcoholic steatohepatitis (NASH). It also reduces hepatocyte ballooning, as well as hepatic lobular inflammation and steatosis in the same model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ren, Q., Chen, Y., Zhou, Z., et al. Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease. J. Med. Chem. 66(9), 6082-6104 (2023).